Alexander Schobel - Aquestive Therapeutics Chief Officer
| AQST Stock | USD 5.16 0.28 5.74% |
Insider
Alexander Schobel is Chief Officer of Aquestive Therapeutics
| Age | 65 |
| Address | 30 Technology Drive, Warren, NJ, United States, 07059 |
| Phone | 908 941 1900 |
| Web | https://www.aquestive.com |
Alexander Schobel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Alexander Schobel against Aquestive Therapeutics stock is an integral part of due diligence when investing in Aquestive Therapeutics. Alexander Schobel insider activity provides valuable insight into whether Aquestive Therapeutics is net buyers or sellers over its current business cycle. Note, Aquestive Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aquestive Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Alexander Schobel over six months ago Disposition of 5895 shares by Alexander Schobel of Aquestive Therapeutics at 4.88 subject to Rule 16b-3 | ||
Alexander Schobel over six months ago Disposition of 25000 shares by Alexander Schobel of Aquestive Therapeutics at 5.1874 subject to Rule 16b-3 | ||
Alexander Schobel over six months ago Sale by Alexander Schobel of 11540 shares of Aquestive Therapeutics | ||
Alexander Schobel over a year ago Acquisition by Alexander Schobel of 50000 shares of Aquestive Therapeutics subject to Rule 16b-3 |
Aquestive Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1557) % which means that it has lost $0.1557 on every $100 spent on assets. This is way below average. Aquestive Therapeutics' management efficiency ratios could be used to measure how well Aquestive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. At this time, Aquestive Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 66.8 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 96.6 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tage MD | Bausch Health Companies | 50 | |
| Brett Icahn | Bausch Health Companies | 41 | |
| Robert Butz | Bausch Health Companies | N/A | |
| Brian McNamara | Haleon plc | 58 | |
| Jeff Hartness | Bausch Health Companies | N/A | |
| Tamara Rogers | Haleon plc | 54 | |
| Amy Landucci | Haleon plc | N/A | |
| CPA CPA | Intracellular Th | 68 | |
| Jooyong Lee | Haleon plc | 47 | |
| Thomas Vadaketh | Bausch Health Companies | 61 | |
| Bart Derde | Haleon plc | 55 | |
| Steven Miller | Bausch Health Companies | 31 | |
| Robert Spurr | Bausch Health Companies | 51 | |
| Sam Will | Bausch Health Companies | N/A | |
| Teri Lyng | Haleon plc | 62 | |
| Mairead Nayager | Haleon plc | 49 | |
| D Hale | Bausch Health Companies | 34 | |
Management Performance
| Return On Asset | -0.16 |
Aquestive Therapeutics Leadership Team
Elected by the shareholders, the Aquestive Therapeutics' board of directors comprises two types of representatives: Aquestive Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aquestive. The board's role is to monitor Aquestive Therapeutics' management team and ensure that shareholders' interests are well served. Aquestive Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aquestive Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carl MD, Chief Officer | ||
| Alexander Schobel, Chief Officer | ||
| BSBA Esq, Sr Counsel | ||
| Kenneth MD, Chief Officer | ||
| Kenneth Marshall, Chief Officer | ||
| Ernest Toth, Chief Officer | ||
| Stephen Wargacki, Senior Development | ||
| Cassie Jung, Senior Operations | ||
| Daniel Barber, Senior Vice President – Chief Strategy and Development Officer | ||
| MBA MD, Chief Officer | ||
| Eric Dadey, VicePres RD | ||
| Sherry Korczynski, Senior Marketing | ||
| Peter Boyd, Senior Vice President – Operations and Value Delivery | ||
| Robert Arnold, Controller Finance | ||
| Keith Kendall, President CEO, Director |
Aquestive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aquestive Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 429.46 M | ||||
| Shares Outstanding | 91.18 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 55.35 % | ||||
| Number Of Shares Shorted | 9.97 M | ||||
| Price To Earning | (1.90) X | ||||
| Price To Sales | 7.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.